uniQure’s (QURE) “Equal Weight” Rating Reiterated at Wells Fargo & Company

Wells Fargo & Company reissued their equal weight rating on shares of uniQure (NASDAQ:QURE) in a research report released on Tuesday morning, Marketbeat Ratings reports. Wells Fargo & Company currently has a $15.00 price target on the biotechnology company’s stock, down from their previous price target of $60.00.

A number of other brokerages have also issued reports on QURE. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday. Stifel Nicolaus set a $14.00 price objective on shares of uniQure in a research note on Monday. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday. Finally, Royal Bank Of Canada downgraded shares of uniQure from a “moderate buy” rating to a “hold” rating and set a $11.00 price target for the company. in a research report on Monday. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $34.33.

uniQure Stock Up 17.8%

QURE stock opened at $10.65 on Tuesday. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50. The firm has a market cap of $665.94 million, a PE ratio of -3.09 and a beta of 0.73. The firm has a 50 day simple moving average of $22.25 and a 200 day simple moving average of $29.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Equities research analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 12,378 shares of uniQure stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the completion of the sale, the chief executive officer owned 639,076 shares of the company’s stock, valued at $15,248,353.36. This trade represents a 1.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 50,598 shares of company stock valued at $1,248,588. 4.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Woodline Partners LP increased its position in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of uniQure in the 2nd quarter valued at approximately $872,000. Teacher Retirement System of Texas acquired a new position in uniQure in the second quarter worth approximately $151,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in uniQure in the second quarter worth approximately $215,000. Finally, SG Americas Securities LLC bought a new position in uniQure during the second quarter valued at approximately $1,321,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Short-term technical/bounce dynamics — commentators note QURE has been deeply oversold and could see a trend reversal as buyers step in on low prices; that dynamic can fuel sharp intraday gains. uniQure (QURE) Loses 67.5% in 4 Weeks
• Positive Sentiment: Elevated trading after recent earnings — coverage notes unusually high volume following uniQure’s recent quarter (the company beat the EPS view), which can amplify swings and supports short-term buyers. uniQure Sees Unusually-High Trading Volume Following Strong Earnings
• Neutral Sentiment: Mixed analyst coverage — some firms (e.g., Mizuho) have issued neutral/hold-type ratings, reflecting uncertainty; this keeps the stock range-bound until regulatory clarity arrives. uniQure Earns Neutral Rating from Mizuho
• Neutral Sentiment: Broker notes and price-target moves are active — these updates increase day-to-day volatility but are secondary to FDA / clinical outcomes for long-term valuation. uniQure Receives Equal Weight Rating from Wells Fargo
• Negative Sentiment: Regulatory risk: senior FDA and HHS officials publicly criticized uniQure’s Huntington’s gene therapy, called it a “failed” product in media remarks, and said a randomized placebo-controlled study is needed — a development that likely delays any Biologics License Application (BLA) approval path and raises clinical/expense uncertainty. Federal health officials attacked an Amsterdam-based biotech company
• Negative Sentiment: Media and agency follow-ups echo the criticism — Reuters, CNBC and others report the FDA defended its call for a new placebo study and said uniQure’s pivotal data do not prove slowed disease progression, reinforcing downside clinical risk. Sr. FDA official calls Uniqure’s Huntington’s disease treatment a failure
• Negative Sentiment: Legal exposure: multiple law firms have filed or circulated class-action notices alleging securities fraud tied to disclosures about the trial design and timing of filings — this raises potential litigation costs, management distraction and settlement risk. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and lower targets — several firms cut price targets and sentiment (Wells Fargo, Chardan, others), which can pressure the stock until regulatory clarity and confirmatory data are provided. Chardan Capital Lowers uniQure Price Target

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.